

abstract

Plerixafor vs G-CSF. Graft composition and main outcomes in pediatric cohort with acute leukemia after $\alpha\beta$ T cell depleted haplo-HSCT

**Svetlana Glushkova, Larisa Shelikhova, Kirill Voronin,
Dmitriy Pershin, Viktoria Vedmedskaya, Yakov Muzalevskii,
Alexei Kazachenok, Elena Kurnikova, Svetlana Radygina,
Maria Ilushina, Rimma Khismatullina, Alexei Maschan,
Michael Maschan**

doi.org/10.69690/ODMJ-018-0425-2612



**SIOP ASIA 2025
SAUDI ARABIA**

ONCODAILY MEDICAL JOURNAL

SIOP ASIA 2025 SAUDI ARABIA

Plerixafor vs G-CSF. Graft composition and main outcomes in pediatric cohort with acute leukemia after $\alpha\beta$ T cell depleted haplo-HSCT

Author: Svetlana Glushkova ¹, Larisa Shelikhova, Kirill Voronin, Dmitriy Pershin, Viktoria Vedmedskaya, Yakov Muzalevskii, Alexei Kazachenok, Elena Kurnikova, Svetlana Radygina, Maria Ilushina, Rimma Khismatullina, Alexei Maschan, Michael Maschan

Affiliation: ¹ Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

DOI: <https://doi.org/10.69690/ODMJ-018-0425-2612>

Introduction: The impact of donor mobilization strategy on graft composition and hematopoietic stem cells transplantation (HSCT) outcomes remains the point of interest.

Methodology: The study cohort includes 295 acute leukemia patients. All patients received their first haplo-HSCT in complete remission with the $\alpha\beta$ T cell depletion method (ProdigyTM, CliniMACSTM by Miltenyi Biotec) from January 2012 to April 2021. The total cohort was divided into two groups by G-CSF + Plerixafor (Mozobil, Genzyme Ltd, Netherlands) or G-CSF donor mobilization strategy, «Plerixafor group» 95(32%) and «G-CSF group» 200(68%) patients accordingly. Relapse and non-relapse mortality (NRM) risks were calculated for each group at 3 years by cumulative risk method (CIR and CI_NRM), groups were compared by Gray's test. The number of graft cells per kg was compared by Mann–Whitney U-test.

Results: The median value (MV) of graft NK cells per kg for G-CSF group was significantly greater than for Plerixafor group ($36 \cdot 10^6$ cells/kg (IQR (25-55) $\cdot 10^6$ cells/kg) vs $25 \cdot 10^6$ cells/kg (IQR (18-36) $\cdot 10^6$ cells/kg), $p < 0.001$). MV of graft stem cells and $\alpha\beta$ T cells for G-CSF group was also greater than for Plerixafor group ($9.94 \cdot 10^6$ cells/kg (IQR (8.00-10.85) $\cdot 10^6$ cells/kg) vs $8.52 \cdot 10^6$ cells/kg (IQR (7.05-10.17) $\cdot 10^6$ cells/kg), $p = 0.002$ for stem cells; $26 \cdot 10^3$ cells/kg, (IQR (14-53) $\cdot 10^3$ cells/kg) vs $22 \cdot 10^3$ cells/kg (IQR (7-39) $\cdot 10^3$ cells/kg), $p = 0.026$ for $\alpha\beta$ T cells accordingly). There were no differences in MV for total CD3+ cells and $\gamma\delta$ T cells subpopulation.

ONCODAILY MEDICAL JOURNAL

SIOP ASIA 2025 SAUDI ARABIA

CI_NRM was significantly higher for the G-CSF group: 8.3% (CI 4.8%-13.0%) in comparison to 1.1% (CI 0.1%-5.5%) for the Plerixafor group, $p=0.021$. On the other hand, CIR was lower for the G-CSF group in comparison to the Plerixafor group (24.7% (CI 18.5%-31.4%) vs 39.0% (CI 28.5%-49.2%) accordingly, $p=0.015$).

Conclusion: Graft NK cells absolute counts per kg were significantly higher for G-CSF group. Plerixafor mobilization group showed improved NRM, while the impact of plerixafor mobilization on the CIR should be further validated in an independent cohort and the mechanisms studied in-depth.